0001661059 false 0001661059 2021-11-04 2021-11-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares











Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): November 4, 2021


NextCure, Inc.

(Exact name of registrant as specified in charter)


Delaware   001-38905   47-5231247

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


9000 Virginia Manor Road, Suite 200

Beltsville, Maryland

(Address of principal executive offices)   (Zip Code)


(240) 399-4900




Registrant’s telephone number, including area code




(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per share NXTC Nasdaq Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 2.02Results of Operations and Financial Condition


On November 4, 2021, NextCure, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2021. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.


The information furnished in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


Item 9.01Financial Statements and Exhibits


(d) Exhibits.




99.1   Press release issued by NextCure, Inc. dated November 4, 2021.
104   Cover Page Interactive Data File (embedded within the inline XBRL document)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 4, 2021  
  /s/ Steven P. Cobourn
  Steven P. Cobourn
  Chief Financial Officer





EX-99.1 2 tm2131564d3_ex99-1.htm EXHIBIT 99.1


Exhibit 99.1


A picture containing clipart

Description automatically generated


NextCure Reports Third Quarter 2021 Financial Results and Provides Business Update


BELTSVILLE, Md. – November 4, 2021NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported third quarter 2021 financial results and provided a business update.


“We are pleased to present clinical and biomarker data for our NC318 and NC410 programs at the upcoming SITC annual meeting,” said Michael Richman, NextCure’s president and chief executive officer. “In addition, we will host a virtual research and development update event following the conference on November 15th. The event will also feature Dr. Roy Herbst who will highlight the significant remaining unmet need in the treatment of lung cancer. Dr Herbst is currently a collaborator in the Phase 2 investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with advanced non-small cell lung cancer.”


Business Highlights and Upcoming Milestones


·Published preclinical data pertaining to the NC410 program in the open access journal, Frontiers in Immunology.

·Appointed Ellen G. Feigal, M.D., a Partner and Head of the Biologics Practice at NDA Partners LLC, and Anne Borgman, M.D., former Vice President and Global Therapeutic Area Lead, Hematology-Oncology, at Jazz Pharmaceuticals, to the Board of Directors.

·Appointed Elizabeth Jaffee, M.D., Ursula Matulonis, M.D., and Weiping Zou, M.D., Ph.D., to its Scientific Advisory Board.

·Clinical and biomarker data for NC318 and NC410 programs to be presented at the upcoming Society for Immunotherapy of Cancer (SITC) annual meeting on November 10-14, 2021.

·Hosting a virtual research and development update event on November 15, 2021, at 4:30 pm EST.

·Announced presentations by collaborators at the American Society of Hematology Annual Meeting (ASH) on December 11-14, 2021, two research studies evaluating the role of Siglec-15 as a therapeutic target in childhood leukemia and the impact of a LAIR-1 antibody that selectively targets AML stem cells.


Financial Guidance


Based on its current research and development plans, NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditure requirements into the second half of 2023.


Financial Results for Quarter Ended September 30, 2021


·Cash, cash equivalents and marketable securities as of September 30, 2021, were $235.3 million, as compared to $283.4 million as of December 31, 2020. The decrease of $48.1 million primarily reflects cash used to fund operations, to purchase fixed assets, and to repay a term loan.

·Research and development expenses were $13.6 million for the quarter ended September 30, 2021, as compared to $12.7 million for the quarter ended September 30, 2020. The increase was driven primarily by clinical-related costs, partially offset by timing of research and manufacturing supply costs.





·General and administrative expenses were $4.9 million for the quarter ended September 30, 2020, as compared to $4.7 million for the quarter ended September 30, 2020. The increase was primarily related to personnel-related costs.

·Net loss was $17.9 million for the quarter ended September 30, 2021, as compared to $16.4 million for the quarter ended September 30, 2020. The increase in net loss for the quarter was primarily due to increased research and development expenses and increased general and administrative expenses from an increase in headcount.


About NextCure, Inc.


NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO™ platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. www.nextcure.com


Forward-Looking Statements


This press release contains forward-looking statements, including statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts, assumptions and other information available to NextCure as of the date hereof. Forward-looking statements include statements regarding NextCure’s expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “may,” “will,” “potential,” “expects,” “believes,” “intends,” “hope,” “towards,” “forward,” “later” and similar expressions. Examples of forward-looking statements in this press release include, among others, statements about the development plans for NC410 and expected upcoming milestones, the potential benefits of NC410, and NextCure’s plans, objectives and intentions with respect to the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impacts of the COVID-19 pandemic on NextCure’s business, including NextCure’s clinical trials, third parties on which NextCure relies and NextCure’s operations; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure’s limited operating history and no products approved for commercial sale; NextCure’s history of significant losses; NextCure’s need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on NextCure’s FIND-IO™ platform; and dependence on key personnel. More detailed information on these and additional factors that could affect NextCure’s actual results are described in NextCure’s filings with the Securities and Exchange Commission (the “SEC”), including in Item 1A of NextCure’s most recent Form 10-K and elsewhere in the Company’s filings with the SEC. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, even if expectations change.







(unaudited, in thousands, except share and per share amounts)


   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2021   2020   2021   2020 
Revenue from former research and development arrangement  $   $   $   $22,378 
Operating expenses:                    
Research and development   13,597    12,740    37,928    34,448 
General and administrative   4,911    4,659    15,766    12,918 
Total operating expenses   18,508    17,399    53,694    47,366 
Loss from operations   (18,508)   (17,399)   (53,694)   (24,988)
Other income, net   578    1,032    1,244    3,846 
Net loss  $(17,930)  $(16,367)  $(52,450)  $(21,142)
Loss per share - basic and diluted  $(0.65)  $(0.59)  $(1.90)  $(0.77)
Weighted-average shares outstanding - basic and diluted   27,615,038    27,547,737    27,607,685    27,524,350 
Comprehensive loss:                    
Net loss  $(17,930)  $(16,367)  $(52,450)  $(21,142)
Unrealized gain (loss) on marketable securities   66    (637)   (908)   1,298 
Total comprehensive loss  $(17,864)  $(17,004)  $(53,358)  $(19,844)







(unaudited, in thousands, except share and per share amounts)


   September 30,   December 31, 
   2021   2020 
Current assets:          
Cash and cash equivalents  $36,664   $32,772 
Marketable securities   198,672    250,676 
Restricted cash   39    1,706 
Prepaid expenses and other current assets   7,661    2,824 
Total current assets   243,036    287,978 
Property and equipment, net   14,208    15,809 
Other assets   581    2,857 
Total assets  $257,825   $306,644 
Liabilities and Stockholders’ Equity          
Current liabilities:          
Accounts payable  $2,946   $3,901 
Accrued liabilities   4,232    4,627 
Deferred rent, current portion   198    130 
Term loan, current portion       1,667 
Total current liabilities   7,376    10,325 
Deferred rent, net of current portion   2,223    792 
Term loan, net of current portion       1,806 
Total liabilities   9,599    12,923 
Stockholders’ equity:          
Preferred stock, par value of $0.001 per share; 10,000,000 shares authorized at September 30, 2021 and December 31, 2020; no shares issued and outstanding at September 30, 2021 and December 31, 2020        
Common stock, par value of $0.001 per share; 100,000,000 shares authorized at September 30, 2021 and December 31, 2020; 27,619,763 and 27,568,802 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively   28    28 
Additional paid-in capital   418,414    410,551 
Accumulated other comprehensive (loss) income   (129)   779 
Accumulated deficit   (170,087)   (117,637)
Total stockholders’ equity   248,226    293,721 
Total liabilities and stockholders’ equity  $257,825   $306,644 





Investor Inquiries


Timothy Mayer, Ph.D.

NextCure, Inc.

Chief Operating Officer

(240) 762-6486





EX-101.SCH 3 nxtc-20211104.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nxtc-20211104_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 nxtc-20211104_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2131564d3_ex99-1img001.jpg GRAPHIC begin 644 tm2131564d3_ex99-1img001.jpg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tm2131564d3_8k_htm.xml IDEA: XBRL DOCUMENT 0001661059 2021-11-04 2021-11-04 iso4217:USD shares iso4217:USD shares 0001661059 false 8-K 2021-11-04 NextCure, Inc. DE 001-38905 47-5231247 9000 Virginia Manor Road Suite 200 Beltsville MD 20705 240 399-4900 false false false false Common Stock, $0.001 par value per share NXTC NASDAQ true false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Nov. 04, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 04, 2021
Entity File Number 001-38905
Entity Registrant Name NextCure, Inc.
Entity Central Index Key 0001661059
Entity Tax Identification Number 47-5231247
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 9000 Virginia Manor Road
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Beltsville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20705
City Area Code 240
Local Phone Number 399-4900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol NXTC
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nextcure.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2131564d3_8k.htm nxtc-20211104.xsd nxtc-20211104_lab.xml nxtc-20211104_pre.xml tm2131564d3_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2131564d3_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2131564d3_8k.htm" ] }, "labelLink": { "local": [ "nxtc-20211104_lab.xml" ] }, "presentationLink": { "local": [ "nxtc-20211104_pre.xml" ] }, "schema": { "local": [ "nxtc-20211104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "NXTC", "nsuri": "http://nextcure.com/20211104", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2131564d3_8k.htm", "contextRef": "From2021-11-04to2021-11-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://nextcure.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2131564d3_8k.htm", "contextRef": "From2021-11-04to2021-11-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://nextcure.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-134399-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-134399-xbrl.zip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